HeiLongJiang ZBD Pharmaceutical Co., Ltd.

HeiLongJiang ZBD Pharmaceutical Co., Ltd. faced a notable decline in its stock price, contrasting with the broader market's modest gains. The company has experienced significant drops over various time frames, alongside persistent financial challenges, including low returns and negative quarterly results, indicating ongoing struggles in profitability and growth.

HeiLongJiang ZBD Pharmaceutical Co., Ltd. faced a notable decline in stock performance, with shares dropping significantly today. The company has experienced substantial setbacks over the past year, reflected in its market capitalization of CNY 6,226 million and poor financial metrics, including low returns and consecutive quarterly losses.

HeiLongJiang ZBD Pharmaceutical Co., Ltd. faced notable volatility on June 11, 2026, closing down significantly. The stock has seen substantial declines over various periods, including a 47.85% drop in the past year. The company reports low profitability and has experienced negative results for three consecutive quarters.

HeiLongJiang ZBD Pharmaceutical Co., Ltd. faced a notable decline in its stock today, contrasting with broader market trends. The company has struggled with profitability, reflected in its low financial metrics and consecutive quarterly losses. Over the past year, it has experienced significant stock depreciation, raising concerns about its future growth prospects.

HeiLongJiang ZBD Pharmaceutical Co., Ltd. faced a notable decline in its stock today, reaching an intraday low. The company has struggled financially, with a low Return on Capital Employed and declining net sales over the past five years. Its annual return has significantly lagged behind the broader market.

HeiLongJiang ZBD Pharmaceutical Co., Ltd. saw a notable decline in stock performance, reflecting ongoing operational challenges. The company has reported negative results for three consecutive quarters and has a low Return on Capital Employed, alongside a high Debt to Equity ratio, indicating financial strain.